We serve Chemical Name:2-[4-(2-methylpropyl)phenyl]propanoyl chloride CAS:34715-60-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![2-[4-(2-methylpropyl)phenyl]propanoyl chloride](https://a.dearchem.com/CAS2/34715-60-1.png)
Chemical Name:2-[4-(2-methylpropyl)phenyl]propanoyl chloride
CAS.NO:34715-60-1
Synonyms:EINECS 252-165-5;OR0555;2-[4-(Isobutyl)phenyl]propionyl chloride;2-(p-isobutylphenyl)propionic acid chloride;2-(4-isobutylphenyl)-propionic acid chloride;2-(4-Isobutylphenyl)propanoyl chloride;2-(p-Isobutylphenyl)propionyl chloride
Molecular Formula:C13H17ClO
Molecular Weight:224.72600
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:295ºC at 760mmHg
Density:1.049g/cm3
Index of Refraction:1.51
PSA:17.07000
Exact Mass:224.09700
LogP:3.75400
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 252-165-5 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(p-Isobutylphenyl)propionyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-isobutylphenyl)-propionic acid chloride Use and application,EINECS 252-165-5 technical grade,usp/ep/jp grade.
Related News: While reactions requiring the use of metal catalysts may necessitate heating to temperatures of 160oC, and/or cooling to -60oC or lower, enzyme-catalyzed reactions instead run at temperatures in the region of ~10 – 40oC. rel-(4R,5R)-3,3-dibutyl-5-(3,4-dimethoxyphenyl)-7-(dimethylamino)-4-hydroxy-2,3,4,5-tetrahydrobenzo[b]thiepine 1,1-dioxide manufacturers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 11-amino-8-bromo-4-oxo-4H-pyrimido[2,1-a]isoquinoline-3-carboxylic acid suppliers ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. 1H-Benzimidazole-1-methanamine, 6-bromo- vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 11-amino-8-bromo-4-oxo-4H-pyrimido[2,1-a]isoquinoline-3-carboxylic acid suppliers ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. 1H-Benzimidazole-1-methanamine, 6-bromo- vendor & factory.
